Dear investors, I’m from Tianjin Fangxin Technology Co., Ltd. My name is Ling Yun. The project I’d like to share with you today is “Cordyceps Sinensis Polyose Emulsion”, which can be rated as a national treasure. According to the plan, RMB 10 million will be raised for the phase 1 of the project by transferring 20% shares. You’re surely familiar with the components and functions of cordyceps sinensis, more or less. As a major component of cordyceps sinensis, cordyceps sinensis polyose is made up of cordycepin, adenosine and polyose (mannose, galactose, arabinose, xylose, glucose, fucose), and has high bioactivity. With the function of consolidating the primordial spirit, strengthening body resistance and eliminating evil, it can be used for immunity regulating, tumor inhibiting, kidney protection, senility deferring, lipid and glycogen metabolism regulating, hepatic fibrosis preventing and radiation resistance. With cordyceps sinensis polyose integrated unsatisfactorily, the similar products available in the market, such as cordyceps sinensis capsule and tablet, cannot give full play to the effects of cordyceps sinensis. Despite this, their sales amount is as high as RMB 3 billion every year. Cordyceps sinensis polyose emulsion is free of the aforesaid problem and more absorbable for human body. As found in testing and small-scale application, the emulsion contains more cordyceps sinensis polyose. One taking the emulsion for 1 month can feel significant change in his physical state. With a wider scope of application, the emulsion is suitable for all of children, the aged and pregnant women, and more profitable than similar products. Sales channel: So far, technical R & D, testing, pilot production and clinical trial have been completed. In these steps, the emulsion makes good effects. This is a project of national level. On the condition that the phase 1 is fully funded, the emulsion can be put on the market in half a year or so. Preliminarily, the emulsion will be sold in the form of food, meanwhile an application will be filed for the qualification of health care product. We have established channels for selling health care products all over the country. On the basis, we will set up our own sales team for the purpose of full coverage. About core team: Ling Yun will take charge of the whole project. He once served in the Central Security Bureau, followed by 5-year work in SOEs and 5-year business startup. In addition, he once participated in an EMBA training at the Renmin University of China and a board secretary training at the Zhongnan University of Economics and Law, and has been awarded a certificate by the Tsinghua University’s SME innovation management (president) seminar. In the team, there are 4 technical engineers. The team head and chief engineer Li is the director of the Jinchanhua (Beijing) International Pharmaceutical Research Institute, the vice director of the Beijing Guokaxin Tumor Research Institute and a member of the Tianjin Medical Research Institute. The commercialization of technological achievements under the project will be completed in half a year or so. We will enter the capital market 3 years later, and endeavor to build the company as an enterprise with marketable value of RMB 10 billion. Destined investors are being expected. We will repay the society and the investors by taking pragmatic actions, and make efforts to improve all people’s health. Thanks. Please attach an introduction in the format of PPT. Detailed testing data and information about the process in laboratory will be made visible after willing investors are confirmed.
Commercial Counsellor's Office
(Please click on the link)
The project is uploaded by the company. Our site doesn’t guarantee the authenticity, accuracy or feasibility of the project information in any form or take any legal responsibility arising from the information.